US5069911A
(en)
*
|
1985-02-05 |
1991-12-03 |
Sandoz Ltd. |
Pharmaceutical 9,10-dihydrogenated ergot alkaloid containing compositions
|
DE3636123A1
(de)
*
|
1986-10-23 |
1988-05-05 |
Rentschler Arzneimittel |
Arzneizubereitungen zur oralen verabreichung, die als einzeldosis 10 bis 240 mg dihydropyridin enthalten
|
FR2618073B1
(fr)
*
|
1987-07-16 |
1990-09-07 |
Pf Medicament |
Comprimes de type a matrice hydrophile a base de salbutamol et leur procede de preparation
|
US4994276A
(en)
*
|
1988-09-19 |
1991-02-19 |
Edward Mendell Co., Inc. |
Directly compressible sustained release excipient
|
DE3741149A1
(de)
*
|
1987-12-04 |
1989-06-15 |
Thomae Gmbh Dr K |
Zubereitungsformen zur verhinderung von adhaesionen von organen und organteilen
|
US5364622A
(en)
*
|
1987-12-04 |
1994-11-15 |
Dr. Karl Thomae Gmbh |
Methods for preventing adhesions to organs and parts of organs by application of tissue plasminogen activator and hydroxyethylcellulose hydrogel
|
US5023080A
(en)
*
|
1988-06-17 |
1991-06-11 |
Basic Bio Systems, Inc. |
Time release protein
|
US5055300A
(en)
*
|
1988-06-17 |
1991-10-08 |
Basic Bio Systems, Inc. |
Time release protein
|
US5079005A
(en)
*
|
1988-06-17 |
1992-01-07 |
Gupta Kashmiri L |
Time release protein
|
US5135757A
(en)
*
|
1988-09-19 |
1992-08-04 |
Edward Mendell Co., Inc. |
Compressible sustained release solid dosage forms
|
US5169639A
(en)
*
|
1988-09-19 |
1992-12-08 |
Edward Mendell Co., Inc. |
Controlled release verapamil tablets
|
HU203041B
(en)
*
|
1989-03-14 |
1991-05-28 |
Egyt Gyogyszervegyeszeti Gyar |
Process for producing pharmaceutical compositions of controlled releasing factor containing nifedipin
|
US5275823A
(en)
*
|
1989-04-27 |
1994-01-04 |
Smith Kline & French Laboratories Ltd. |
Pharmaceutical compositions
|
DE69115974T2
(de)
*
|
1990-04-09 |
1996-05-23 |
Produits Refractaires |
Kalorienarme gepresste Tabletten mit verbessertem Mundgefühl
|
US5403593A
(en)
*
|
1991-03-04 |
1995-04-04 |
Sandoz Ltd. |
Melt granulated compositions for preparing sustained release dosage forms
|
US5221698A
(en)
*
|
1991-06-27 |
1993-06-22 |
The Regents Of The University Of Michigan |
Bioactive composition
|
US5225201A
(en)
*
|
1991-08-23 |
1993-07-06 |
Minnesota Mining And Manufacturing Company |
Salsalate tablet
|
FI93924C
(fi)
*
|
1991-09-17 |
1995-06-26 |
Martti Lauri Antero Marvola |
Menetelmä säädellysti lääkeainetta vapauttavan valmisteen valmistamiseksi
|
CA2082185C
(fr)
*
|
1991-11-26 |
2004-01-20 |
Alexander R. Pokora |
Traitement catalytique de matieres lignocellulosiques a l'aide de protease
|
US5266331A
(en)
*
|
1991-11-27 |
1993-11-30 |
Euroceltique, S.A. |
Controlled release oxycodone compositions
|
US5968551A
(en)
*
|
1991-12-24 |
1999-10-19 |
Purdue Pharma L.P. |
Orally administrable opioid formulations having extended duration of effect
|
US5958459A
(en)
*
|
1991-12-24 |
1999-09-28 |
Purdue Pharma L.P. |
Opioid formulations having extended controlled released
|
US5478577A
(en)
*
|
1993-11-23 |
1995-12-26 |
Euroceltique, S.A. |
Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
|
GB9200607D0
(en)
*
|
1992-01-13 |
1992-03-11 |
Ethical Pharma Ltd |
Pharmaceutical compositions containing nifedipine and process for the preparation thereof
|
US5472711A
(en)
*
|
1992-07-30 |
1995-12-05 |
Edward Mendell Co., Inc. |
Agglomerated hydrophilic complexes with multi-phasic release characteristics
|
US20080075781A1
(en)
*
|
1992-11-25 |
2008-03-27 |
Purdue Pharma Lp |
Controlled release oxycodone compositions
|
USRE39300E1
(en)
|
1993-01-28 |
2006-09-19 |
Virginia Commonwealth University Medical College Of Virginia |
Inhibiting the development of tolerance to and/or dependence on an addictive substance
|
US5321012A
(en)
*
|
1993-01-28 |
1994-06-14 |
Virginia Commonwealth University Medical College |
Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
|
NZ260408A
(en)
|
1993-05-10 |
1996-05-28 |
Euro Celtique Sa |
Controlled release preparation comprising tramadol
|
US20070275062A1
(en)
*
|
1993-06-18 |
2007-11-29 |
Benjamin Oshlack |
Controlled release oxycodone compositions
|
US7740881B1
(en)
|
1993-07-01 |
2010-06-22 |
Purdue Pharma Lp |
Method of treating humans with opioid formulations having extended controlled release
|
IL110014A
(en)
*
|
1993-07-01 |
1999-11-30 |
Euro Celtique Sa |
Solid controlled-release oral dosage forms of opioid analgesics
|
US5879705A
(en)
*
|
1993-07-27 |
1999-03-09 |
Euro-Celtique S.A. |
Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
|
US6818229B1
(en)
|
1993-09-20 |
2004-11-16 |
Kos Pharmaceuticals, Inc. |
Intermediate release nicotinic acid compositions for treating hyperlipidemia
|
US6129930A
(en)
|
1993-09-20 |
2000-10-10 |
Bova; David J. |
Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
|
US6676967B1
(en)
|
1993-09-20 |
2004-01-13 |
Kos Pharmaceuticals, Inc. |
Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
|
US6746691B2
(en)
|
1993-09-20 |
2004-06-08 |
Kos Pharmaceuticals, Inc. |
Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
|
US6080428A
(en)
|
1993-09-20 |
2000-06-27 |
Bova; David J. |
Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
|
US20060263428A1
(en)
*
|
1993-09-20 |
2006-11-23 |
Eugenio Cefali |
Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics
|
KR100354702B1
(ko)
*
|
1993-11-23 |
2002-12-28 |
유로-셀티크 소시에떼 아노뉨 |
약학조성물의제조방법및서방형조성물
|
US5891471A
(en)
*
|
1993-11-23 |
1999-04-06 |
Euro-Celtique, S.A. |
Pharmaceutical multiparticulates
|
US5843480A
(en)
*
|
1994-03-14 |
1998-12-01 |
Euro-Celtique, S.A. |
Controlled release diamorphine formulation
|
GB9422154D0
(en)
|
1994-11-03 |
1994-12-21 |
Euro Celtique Sa |
Pharmaceutical compositions and method of producing the same
|
US20020006438A1
(en)
*
|
1998-09-25 |
2002-01-17 |
Benjamin Oshlack |
Sustained release hydromorphone formulations exhibiting bimodal characteristics
|
US5965161A
(en)
|
1994-11-04 |
1999-10-12 |
Euro-Celtique, S.A. |
Extruded multi-particulates
|
US5744164A
(en)
*
|
1994-12-16 |
1998-04-28 |
Nestec S.A. |
Sustained release microparticulate caffeine formulation
|
EP0742008A1
(fr)
*
|
1995-05-11 |
1996-11-13 |
Euro-Celtique S.A. |
Compositions pharmaceutiques à libération contrÔlée
|
US5931809A
(en)
|
1995-07-14 |
1999-08-03 |
Depotech Corporation |
Epidural administration of therapeutic compounds with sustained rate of release
|
GB9519363D0
(en)
|
1995-09-22 |
1995-11-22 |
Euro Celtique Sa |
Pharmaceutical formulation
|
IT1276130B1
(it)
|
1995-11-14 |
1997-10-27 |
Gentili Ist Spa |
Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
|
US20060068018A1
(en)
*
|
1996-03-25 |
2006-03-30 |
Wyeth |
Extended release formulation
|
SE9704401D0
(sv)
*
|
1997-11-28 |
1997-11-28 |
Astra Ab |
Matrix pellets for greasy, oily or sticky drug substances
|
PT1685839E
(pt)
|
1997-12-22 |
2013-07-08 |
Euro Celtique Sa |
Forma de dosagem farmacêutica por via oral compreendendo uma combinação de um agonista opióide e de um antagonista opióide
|
KR100417490B1
(ko)
*
|
1997-12-22 |
2004-02-05 |
유로-셀티크 소시에떼 아노뉨 |
오피오이드 제형의 남용을 방지하는 방법
|
CN1203846C
(zh)
|
1998-03-19 |
2005-06-01 |
布里斯托尔-迈尔斯斯奎布公司 |
高溶解性药物的双相控释递送系统和方法
|
US6099859A
(en)
|
1998-03-20 |
2000-08-08 |
Andrx Pharmaceuticals, Inc. |
Controlled release oral tablet having a unitary core
|
US6806294B2
(en)
|
1998-10-15 |
2004-10-19 |
Euro-Celtique S.A. |
Opioid analgesic
|
UA74141C2
(uk)
|
1998-12-09 |
2005-11-15 |
Дж.Д. Сірл Енд Ко. |
Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
|
US6419960B1
(en)
|
1998-12-17 |
2002-07-16 |
Euro-Celtique S.A. |
Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
|
US6673367B1
(en)
*
|
1998-12-17 |
2004-01-06 |
Euro-Celtique, S.A. |
Controlled/modified release oral methylphenidate formulations
|
DE19918325A1
(de)
|
1999-04-22 |
2000-10-26 |
Euro Celtique Sa |
Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
|
US6555139B2
(en)
|
1999-06-28 |
2003-04-29 |
Wockhardt Europe Limited |
Preparation of micron-size pharmaceutical particles by microfluidization
|
US6878749B2
(en)
*
|
1999-09-17 |
2005-04-12 |
Novartis Ag |
Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
|
US10179130B2
(en)
|
1999-10-29 |
2019-01-15 |
Purdue Pharma L.P. |
Controlled release hydrocodone formulations
|
WO2001035961A1
(fr)
|
1999-10-29 |
2001-05-25 |
Nitromed, Inc. |
Methodes de traitement de maladies vasculaires caracterisees par une insuffisance du monoxyde d'azote
|
US7537785B2
(en)
*
|
1999-10-29 |
2009-05-26 |
Nitromed, Inc. |
Composition for treating vascular diseases characterized by nitric oxide insufficiency
|
KR20130010512A
(ko)
|
1999-10-29 |
2013-01-28 |
유로-셀티크 소시에떼 아노뉨 |
서방성 하이드로코돈 제형
|
US7771746B2
(en)
*
|
1999-12-03 |
2010-08-10 |
Polichem Sa |
Methods for making sustained-release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof
|
AU776904B2
(en)
|
2000-02-08 |
2004-09-23 |
Euro-Celtique S.A. |
Controlled-release compositions containing opioid agonist and antagonist
|
US6565882B2
(en)
|
2000-02-24 |
2003-05-20 |
Advancis Pharmaceutical Corp |
Antibiotic composition with inhibitor
|
US6544555B2
(en)
|
2000-02-24 |
2003-04-08 |
Advancis Pharmaceutical Corp. |
Antibiotic product, use and formulation thereof
|
US6855721B1
(en)
|
2000-07-28 |
2005-02-15 |
Indevus Pharmaceuticals, Inc. |
Methods and compositions for alleviating stuttering
|
SE0003125D0
(sv)
*
|
2000-09-05 |
2000-09-05 |
Astrazeneca Ab |
Modified polymers
|
US6541014B2
(en)
|
2000-10-13 |
2003-04-01 |
Advancis Pharmaceutical Corp. |
Antiviral product, use and formulation thereof
|
US20020068078A1
(en)
|
2000-10-13 |
2002-06-06 |
Rudnic Edward M. |
Antifungal product, use and formulation thereof
|
KR100960200B1
(ko)
|
2000-10-30 |
2010-05-27 |
유로-셀티크 소시에떼 아노뉨 |
서방성 하이드로코돈 제형
|
US20020197314A1
(en)
*
|
2001-02-23 |
2002-12-26 |
Rudnic Edward M. |
Anti-fungal composition
|
UA81224C2
(uk)
*
|
2001-05-02 |
2007-12-25 |
Euro Celtic S A |
Дозована форма оксикодону та її застосування
|
US20110104214A1
(en)
|
2004-04-15 |
2011-05-05 |
Purdue Pharma L.P. |
Once-a-day oxycodone formulations
|
DE60238756D1
(de)
|
2001-05-11 |
2011-02-10 |
Endo Pharmaceuticals Inc |
Opioid enthaltende arzneiform gegen missbrauch
|
WO2003007802A2
(fr)
*
|
2001-07-18 |
2003-01-30 |
Euro-Celtique, S.A. |
Combinaisons pharmaceutiques d'oxycodone et naloxone
|
EP1408976B3
(fr)
*
|
2001-07-20 |
2010-08-25 |
Psychogenics Inc. |
Traitement des troubles de deficit de l'attention/hyperactivite
|
US20030044458A1
(en)
*
|
2001-08-06 |
2003-03-06 |
Curtis Wright |
Oral dosage form comprising a therapeutic agent and an adverse-effect agent
|
JP4504013B2
(ja)
|
2001-08-06 |
2010-07-14 |
ユーロ−セルティーク エス.エイ. |
放出可能な及び封鎖されたアンタゴニストを有するオピオイドアゴニスト製剤
|
AU2002324624A1
(en)
*
|
2001-08-06 |
2003-02-24 |
Euro-Celtique S.A. |
Sequestered antagonist formulations
|
US11207805B2
(en)
|
2001-10-12 |
2021-12-28 |
Aquestive Therapeutics, Inc. |
Process for manufacturing a resulting pharmaceutical film
|
US7357891B2
(en)
|
2001-10-12 |
2008-04-15 |
Monosol Rx, Llc |
Process for making an ingestible film
|
US20190328679A1
(en)
|
2001-10-12 |
2019-10-31 |
Aquestive Therapeutics, Inc. |
Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
|
US20110033542A1
(en)
|
2009-08-07 |
2011-02-10 |
Monosol Rx, Llc |
Sublingual and buccal film compositions
|
US8900498B2
(en)
|
2001-10-12 |
2014-12-02 |
Monosol Rx, Llc |
Process for manufacturing a resulting multi-layer pharmaceutical film
|
US8900497B2
(en)
|
2001-10-12 |
2014-12-02 |
Monosol Rx, Llc |
Process for making a film having a substantially uniform distribution of components
|
US8765167B2
(en)
|
2001-10-12 |
2014-07-01 |
Monosol Rx, Llc |
Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
|
US20070281003A1
(en)
|
2001-10-12 |
2007-12-06 |
Fuisz Richard C |
Polymer-Based Films and Drug Delivery Systems Made Therefrom
|
US10285910B2
(en)
|
2001-10-12 |
2019-05-14 |
Aquestive Therapeutics, Inc. |
Sublingual and buccal film compositions
|
US8603514B2
(en)
|
2002-04-11 |
2013-12-10 |
Monosol Rx, Llc |
Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
|
TWI312285B
(en)
|
2001-10-25 |
2009-07-21 |
Depomed Inc |
Methods of treatment using a gastric retained gabapentin dosage
|
US20060159743A1
(en)
*
|
2001-10-25 |
2006-07-20 |
Depomed, Inc. |
Methods of treating non-nociceptive pain states with gastric retentive gabapentin
|
US7612112B2
(en)
|
2001-10-25 |
2009-11-03 |
Depomed, Inc. |
Methods of treatment using a gastric retained gabapentin dosage
|
DE20308437U1
(de)
|
2002-04-05 |
2003-11-13 |
Euroceltique S.A., Luxemburg/Luxembourg |
Matrix zur verzögerten, gleichbleibenden und unabhängigen Freisetzung von Wirkstoffen
|
EP1515674A4
(fr)
*
|
2002-05-13 |
2008-04-09 |
Endo Pharmaceuticals Inc |
Forme pharmaceutique solide opioide a l'epreuve des abus d'opioides
|
WO2004041154A2
(fr)
*
|
2002-05-13 |
2004-05-21 |
Endo Pharmaceuticals Inc. |
Forme posologique opioide empechant une utilisation abusive
|
WO2003105809A1
(fr)
|
2002-06-17 |
2003-12-24 |
Themis Laboratories Private Limited |
Comprimes multicouche contenant des thiazolidinediones et des biguanides et procedes de production desdits comprimes
|
EP1549296A4
(fr)
*
|
2002-08-02 |
2006-08-09 |
Penwest Pharmaceuticals Co |
Preparations a liberation soutenue de metformine
|
EP2422775A3
(fr)
|
2002-09-20 |
2012-04-18 |
Alpharma, Inc. |
Séquestration de sous-unité et compositions et procédés associés
|
US20040086566A1
(en)
*
|
2002-11-04 |
2004-05-06 |
Alpharma, Inc. |
Waxy matrix dosage forms
|
US20040202717A1
(en)
|
2003-04-08 |
2004-10-14 |
Mehta Atul M. |
Abuse-resistant oral dosage forms and method of use thereof
|
MY135852A
(en)
*
|
2003-04-21 |
2008-07-31 |
Euro Celtique Sa |
Pharmaceutical products
|
US20050042289A1
(en)
*
|
2003-04-29 |
2005-02-24 |
Yamanouchi Pharma Technologies, Inc. |
Tablets and methods for modified release of hydrophylic and other active agents
|
PT2316456T
(pt)
|
2003-04-29 |
2017-09-05 |
Orexigen Therapeutics Inc |
Composições para afetar a perda de peso compreendendo naltrexona e bupropion
|
BR0302017B1
(pt)
*
|
2003-06-02 |
2014-10-29 |
Ems Sigma Pharma Ltda |
Composição farmacêutica sublingual a base de um agonista do receptor central de benzodiazepínicos
|
JP2006528190A
(ja)
|
2003-07-21 |
2006-12-14 |
アドバンシス ファーマスーティカル コーポレイション |
抗生物質製剤、その使用法及び作成方法
|
US8313776B2
(en)
|
2003-07-21 |
2012-11-20 |
Shionogi Inc. |
Antibiotic product, use and formulation thereof
|
JP2006528185A
(ja)
|
2003-07-21 |
2006-12-14 |
アドバンシス ファーマスーティカル コーポレイション |
抗生物質製剤、その使用法及び作成方法
|
CA2535177A1
(fr)
|
2003-08-11 |
2005-02-24 |
Advancis Pharmaceutical Corporation |
Pastille robuste
|
CA2535398C
(fr)
|
2003-08-12 |
2013-11-12 |
Advancis Pharmaceuticals Corporation |
Antibiotique, utilisation et formulation associees
|
AU2004270170B2
(en)
|
2003-08-29 |
2011-01-27 |
Shionogi, Inc. |
Antibiotic product, use and formulation thereof
|
WO2005027877A1
(fr)
|
2003-09-15 |
2005-03-31 |
Advancis Pharmaceutical Corporation |
Antibiotique, son utilisation et sa formulation
|
ES2359375T3
(es)
*
|
2003-11-04 |
2011-05-20 |
Supernus Pharmaceuticals, Inc. |
Formas de dosificación de dosis única diaria de trospio.
|
WO2005046663A1
(fr)
|
2003-11-04 |
2005-05-26 |
Shire Laboratories, Inc. |
Composes d'ammonium quaternaire contenant des activateurs de la biodisponibilite
|
US20050202079A1
(en)
*
|
2004-03-15 |
2005-09-15 |
Mylan Pharmaceuticals Inc. |
Novel orally administrable formulation of nitrofurantoin and a method for preparing said formulation
|
RU2388466C2
(ru)
|
2004-04-27 |
2010-05-10 |
Медисинова, Инк. |
Производные феноксиалкилкарбоновых кислот при лечении воспалительных заболеваний
|
US7691874B2
(en)
*
|
2004-05-14 |
2010-04-06 |
Hyoung-Chun KIM |
Neuroprotective properties of dextrorotatory morphinans
|
EP1604666A1
(fr)
*
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioides pour le traitement de la bronchopneumopathie chronique obstructive
|
JP2008505124A
(ja)
|
2004-07-02 |
2008-02-21 |
アドバンシス ファーマスーティカル コーポレイション |
パルス送達用錠剤
|
FR2875409B1
(fr)
*
|
2004-09-17 |
2010-05-07 |
Sanofi Aventis |
Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose
|
EP2623099A1
(fr)
|
2004-11-24 |
2013-08-07 |
Neuromolecular Pharmaceuticals, Inc |
Composition et procédé de traitement d'une maladie neurologique
|
EP1702558A1
(fr)
*
|
2005-02-28 |
2006-09-20 |
Euro-Celtique S.A. |
Procédé et dispositif pour évaluer la fonction de l'activité intestinale
|
NZ561375A
(en)
|
2005-06-27 |
2011-06-30 |
Biovail Lab Int Srl |
Bupropion hydrobromide, and crystalline forms, compositions, and uses of this compound
|
WO2007056205A2
(fr)
*
|
2005-11-04 |
2007-05-18 |
Eastman Chemical Company |
Esters de carboxyalkylcellulose pour administration d'agents pharmaceutiquement actifs peu solubles
|
ES2761812T3
(es)
|
2005-11-22 |
2020-05-21 |
Nalpropion Pharmaceuticals Inc |
Composición y métodos de aumento de la sensibilidad a la insulina
|
US8357394B2
(en)
|
2005-12-08 |
2013-01-22 |
Shionogi Inc. |
Compositions and methods for improved efficacy of penicillin-type antibiotics
|
US8778924B2
(en)
|
2006-12-04 |
2014-07-15 |
Shionogi Inc. |
Modified release amoxicillin products
|
US20090176882A1
(en)
|
2008-12-09 |
2009-07-09 |
Depomed, Inc. |
Gastric retentive gabapentin dosage forms and methods for using same
|
US8299052B2
(en)
*
|
2006-05-05 |
2012-10-30 |
Shionogi Inc. |
Pharmaceutical compositions and methods for improved bacterial eradication
|
US8916195B2
(en)
|
2006-06-05 |
2014-12-23 |
Orexigen Therapeutics, Inc. |
Sustained release formulation of naltrexone
|
US20070281017A1
(en)
*
|
2006-06-06 |
2007-12-06 |
Endo Pharmaceuticals Inc., A Delaware Corporation |
Sustained release oxycodone composition with acrylic polymer and metal hydroxide
|
SI2484346T1
(sl)
|
2006-06-19 |
2017-05-31 |
Alpharma Pharmaceuticals Llc |
Farmacevtski sestavki
|
US20080069871A1
(en)
*
|
2006-07-21 |
2008-03-20 |
Vaughn Jason M |
Hydrophobic abuse deterrent delivery system
|
CA2668885C
(fr)
|
2006-11-09 |
2016-08-02 |
Orexigen Therapeutics, Inc. |
Procedes d'administration de medications pour la perte de poids
|
US20100151014A1
(en)
*
|
2008-12-16 |
2010-06-17 |
Alpharma Pharmaceuticals, Llc |
Pharmaceutical composition
|
US8623418B2
(en)
|
2007-12-17 |
2014-01-07 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical composition
|
US20090246276A1
(en)
|
2008-01-28 |
2009-10-01 |
Graham Jackson |
Pharmaceutical Compositions
|
CA2725930A1
(fr)
|
2008-05-30 |
2009-12-30 |
Orexigen Therapeutics, Inc. |
Procedes pour traiter des pathologies des graisses viscerales
|
MY150600A
(en)
*
|
2008-07-07 |
2014-01-30 |
Euro Celtique Sa |
Use of opioid antagonists for treating urinary retention
|
ES2613673T3
(es)
|
2008-08-20 |
2017-05-25 |
Cargill, Incorporated |
Nuevo material de polidextrosa
|
PT2405915T
(pt)
|
2009-03-10 |
2019-01-29 |
Euro Celtique Sa |
Composições farmacêuticas de libertação imediata compreendendo oxicodona e naloxona
|
WO2011044545A2
(fr)
|
2009-10-09 |
2011-04-14 |
Sigalov Alexander B |
Procédés et compositions pour une imagerie ciblée
|
BR112012013487A2
(pt)
|
2009-12-02 |
2017-10-03 |
Adamas Pharmaceuticals Inc |
Composições de amantadina e métodos de uso
|
KR101841442B1
(ko)
|
2010-01-11 |
2018-03-23 |
오렉시젠 세러퓨틱스 인크. |
주우울증 환자들에 있어서 체중 감량 치료를 제공하는 방법
|
US9149959B2
(en)
|
2010-10-22 |
2015-10-06 |
Monosol Rx, Llc |
Manufacturing of small film strips
|
US8835499B2
(en)
|
2011-12-08 |
2014-09-16 |
Medicinova, Inc. |
Method of treating non-alcoholic fatty liver disease and steatohepatitis
|
US8962687B2
(en)
|
2012-12-05 |
2015-02-24 |
Medicinova, Inc. |
Method of treating liver disorders
|
WO2013130354A1
(fr)
|
2012-02-29 |
2013-09-06 |
University Hospitals Cleveland Medical Center |
Traitement ciblé de cancer anaérobie
|
EP2858640B1
(fr)
|
2012-06-06 |
2020-03-25 |
Nalpropion Pharmaceuticals LLC |
Composition à être utilisée dans une méthode de traitement de la surcharge pondérale et de l'obésité dans de patients présentant un risque cardiovasculaire élevé
|
WO2013184902A1
(fr)
|
2012-06-07 |
2013-12-12 |
Board Of Regents, The University Of Texas System |
Transformations chimiques de (-)-codéine pour fournir des dérivés de codéine et de morphine correspondants
|
RU2015105097A
(ru)
*
|
2012-08-23 |
2016-10-10 |
Кардиолинкс Аг |
Композиции аминоалкилнитрата с пролонгированным высвобождением
|
US10154971B2
(en)
|
2013-06-17 |
2018-12-18 |
Adamas Pharma, Llc |
Methods of administering amantadine
|
NZ716267A
(en)
|
2013-07-23 |
2017-05-26 |
Euro Celtique Sa |
A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
|
US20150031769A1
(en)
|
2013-07-25 |
2015-01-29 |
Medicinova, Inc. |
Methods for reducing triglyceride, total cholesterol and low density lipoprotein blood levels
|
CA2930001A1
(fr)
|
2013-11-11 |
2015-05-14 |
University Hospitals Cleveland Medical Center |
Traitement cible de cancer anaerobie
|
US8969371B1
(en)
|
2013-12-06 |
2015-03-03 |
Orexigen Therapeutics, Inc. |
Compositions and methods for weight loss in at risk patient populations
|
US9346754B2
(en)
|
2014-05-08 |
2016-05-24 |
Medicinova, Inc. |
Method of treating advanced non-alcoholic steatohepatitis
|
US20150321989A1
(en)
|
2014-05-08 |
2015-11-12 |
Medicinova, Inc. |
Method of treating idiopathic pulmonary fibrosis
|
KR102435793B1
(ko)
|
2014-06-02 |
2022-08-25 |
메디시노바, 인크. |
섬유증의 억제 또는 치료 방법
|
CA2936746C
(fr)
|
2014-10-31 |
2017-06-27 |
Purdue Pharma |
Methodes et compositions destinees au traitement du trouble de deficit d'attention
|
KR102462638B1
(ko)
|
2014-11-26 |
2022-11-03 |
메디시노바, 인크. |
이부딜라스트와 릴루졸의 배합물 및 이의 사용방법
|
US9943513B1
(en)
|
2015-10-07 |
2018-04-17 |
Banner Life Sciences Llc |
Opioid abuse deterrent dosage forms
|
US10335405B1
(en)
|
2016-05-04 |
2019-07-02 |
Patheon Softgels, Inc. |
Non-burst releasing pharmaceutical composition
|
US11273131B2
(en)
|
2016-05-05 |
2022-03-15 |
Aquestive Therapeutics, Inc. |
Pharmaceutical compositions with enhanced permeation
|
KR20230137362A
(ko)
|
2016-05-05 |
2023-10-04 |
어퀘스티브 테라퓨틱스, 아이엔씨. |
강화된 전달 에프네프린 조성물
|
US10335375B2
(en)
|
2017-05-30 |
2019-07-02 |
Patheon Softgels, Inc. |
Anti-overingestion abuse deterrent compositions
|
AU2018360383A1
(en)
|
2017-11-02 |
2020-05-21 |
Natureceuticals Sdn. Bhd. |
Extract of orthosiphon stamineus, formulations, and uses thereof
|
US10722473B2
(en)
|
2018-11-19 |
2020-07-28 |
Purdue Pharma L.P. |
Methods and compositions particularly for treatment of attention deficit disorder
|
EP3897728A1
(fr)
*
|
2018-12-18 |
2021-10-27 |
DDP Specialty Electronic Materials US, Inc. |
Composition à libération prolongée comprenant une méthylcellulose hydroxyalkyle
|
CA3217719A1
(fr)
|
2021-05-28 |
2022-12-01 |
Kazuko Matsuda |
Derives d'acide phenoxyalkylcarboxylique et leur utilisation pour abaisser les taux de triglycerides
|